FRI0238 The level of leptin in patients with gout and its association with the gout activity score. (12th June 2018)

• Record Type: Journal Article
• Authors: Orlova, I.; Stanislavchuk, M.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 660
• Page End: 660
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.4528
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Leptin is a cytokine-like hormone mainly produced by adipose tissue. Its role in inflammation, obesity, diabetes mellitus, and cardiovascular pathology is well known. 2 Most of these pathological conditions usually acompany gout, but role of leptin in gout remains on the discussion. Objectives: To determine the level of leptin in patients with gout and evaluate its association with the disease activity. Methods: Study involved 151 patients with gout (100% men), aged (mean ±SD) 52.4±9.2 years, with a disease duration 8.9±6.6 years. In 51 (33.7%) was diagnosed tophaceous gout. Contol group was represented by 31 healthy subjects. Diagnosis of gout was based on the ACR/EULAR 2015 criteria. The disease activity was determined by the Gout Activity Score (GAS), 2 the intensity of the pain – by the visual analogue scale (VASpain ). Leptin in serum was determined by ELISA. Results: The level of leptin in patients with gout was 2 times higher compare to those in the control group (6.6±4.3 vs 3.0±1.4 ng/ml). The number of attacks in the last year was 3.9±2.7, number of affected joints was 8, 1±5, 4, and uric acid in serum (sUA) was 8.1±2.0 mg/dl. Mean value of VASpain in gout patients was 5.4±2.4 cm, and disease activity by GAS – 5.9±2.1. Regarding GAS we divided our patients in three groups: low activity (GAS <25 th percentile), moderate activity (between 25th and 75th percentile) and high activity (>75 th percentile). In 36 patients with high disease activity (GAS >7.4) the level of leptin was the highest (11.7±4.7 ng/ml), whereas in patients with moderate activity (GAS 4.5–7.4; n=77) and in patients with low disease activity (GAS <4.5; n=38) it was 5.3±2.6 ng/ml and 3.9±1.4 ng/ml, respectively. The difference in leptin levels between all groups was significant (p<0.01). The level of leptin correlated with the number of gout attacks (r=0.41), number of affected joints (r=0.55), sUA (r=0.39), VASpain (r=0.35), and GAS (r=0.69). Conclusions: Association of increased leptin level with high gout activity may indicate possible pathogenic role of leptin in gout. GAS is reliable and sensitive clinical tool for determining disease activity in patients with gout. References: [1] Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. International journal of molecular sciences2014;15(4):6184–6223. [2] Scirè CA, Carrara G, Viroli C, Cimmino MA, Taylor WJ, Manara M, Matucci-Cerinic M. Development and first validation of a disease activity score for gout. Arthritis care & research2016;68(10):1530–1537. Disclosure of Interest: None declared